Please assess the completion status of the following clinical trial:

Trial Title: Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes patients with diabetic nephropathy in the range of micro- or macroalbuminuria~* treatment with combination of enalapril and losartan for more than one year~Exclusion Criteria:~* history of non-adherence to prescribed medication assessed by the prescribing physician~* baseline potassium \> 5.5 meq/L~* chronic kidney disease stages 4 or 5~* history or evidence of non-diabetic kidney disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ACE/ARB (Type: NO_INTERVENTION): In 62 patients previously treated with enalapril (10-30 mg daily) + losartan (50-100 mg daily), this regimen was continued.
- Spironolactone/ARB (Type: ACTIVE_COMPARATOR): spironolacone 25 mg tablets added to losartan

Based on this trial design, predict the completion outcome and termination type (if applicable).